Public–private collaborations in drug development: boosting innovation or alleviating risk?

References

• Anderson, E., and S. D. Jap. 2005. “The Dark Side of Close Relationships.” MIT Sloan Management Review 46 (3): 75–82.
   Web of Science ®Google Scholar
• Andrews, R., and T. Entwistle. 2010. “Does Cross-Sectoral Partnership Deliver? an Empirical Exploration of Public Service Effectiveness, Efficiency, and Equity.” Journal of Public Administration and Research Theory 20 (3): 679–701. doi:10.1093/jopart/mup045.
   Web of Science ®Google Scholar
• Babiak, K., and L. Thibault. 2009. “Challenges in Multiple Cross-Sector Partnerships.” Nonprofit and Voluntary Sector Quarterly 38 (1): 117–143. doi:10.1177/0899764008316054.
   Web of Science ®Google Scholar
• Bland, T., B. Bruk, D. Kim, and K. T. Lee. 2010. “Enhancing Public Sector Innovation: Examining the Network-Innovation Relationship.” The Innovation Journal: The Public Sector Innovation Journal 15 (3): 1–17.
   Google Scholar
• Boyer, E. J., D. M. Van Slyke, and J. D. Rogers. 2016. “An Empirical Examination of Public Involvement in Public-Private Partnerships: Qualifying the Benefits of Public Involvement in Ppps.” Journal of Public Administration and Research Theory 26: 45–61.
   Web of Science ®Google Scholar
• Brown, L., and S. P. Osborne. 2013. “Risk and Innovation: Towards a Framework for Risk Governance in Public Services.” Public Management Review 15 (2): 186–208. doi:10.1080/14719037.2012.707681.
   Web of Science ®Google Scholar
• Bryson, J. M., B. C. Crosby, and M. M. Stone. 2006. “The Design and Implementation of Cross‐Sector Collaborations: Propositions from the Literature.” Public Administration Review 66 (s1): 44–55. doi:10.1111/j.1540-6210.2006.00665.x.
   Web of Science ®Google Scholar
• Chakrabarti, A. K., and U. Weisenfeld. 1991. “An Empirical Analysis of Innovation Strategies of Biotechnology Firms in the U.S.” Journal of Engineering and Technology Management 8 (3–4): 243–260. doi:10.1016/0923-4748(91)90013-H.
   Google Scholar
• Chen, C., M. Hubbard, and C.-S. Liao. 2013. “When Public–Private Partnerships Fail: Analysing Citizen Engagement in Public–Private Partnerships–Cases from Taiwan and China.” Public Management Review 15 (6): 839–857. doi:10.1080/14719037.2012.698856.
   Web of Science ®Google Scholar
• Cockburn, I. M. 2007. “Is the Pharmaceutical Industry in a Productivity Crisis?” In In Innovation Policy and the Economy, edited by J. Lerner and S. Stern, 1–32. Vol. 7. Cambridge, MA: MIT Press.
   Google Scholar
• Cohen, F. J. 2005. “Macro Trends in Pharmaceutical Innovation.” Nature Reviews Drug Discovery 4 (1): 78–84. doi:10.1038/nrd1610.
   PubMed Web of Science ®Google Scholar
• Danzon, P. M., S. Nicholson, and N. S. Pereira. 2005. “Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances.” Journal of Health Economics 24 (2): 317–339. doi:10.1016/j.jhealeco.2004.09.006.
   PubMed Web of Science ®Google Scholar
• DiMasi, J. A. 2001. “Risks in New Drug Development: Approval Risks in New Drug Development: Approval Success Rates for Investigational Drugs.” Clinical Pharmacology Therapeutics 69 (5): 297–307. doi:10.1067/mcp.2001.115446.
   PubMed Web of Science ®Google Scholar
• DiMasi, J. A., and H. G. Grabowski. 2007. “The Cost of Biopharmaceutical R&D: Is Biotech Different?” Managerial and Decision Economics 28 (4–5): 469–479. doi:10.1002/mde.1360.
   Google Scholar
• DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003. “The Price of Innovation: New Estimates of Drug Development Costs.” Journal of Health Economics 22 (2): 151–185. doi:10.1016/S0167-6296(02)00126-1.
   PubMed Web of Science ®Google Scholar
• Ernst & Young. 2011. Beyond Borders: Global Biotechnology Report 2011. Accessed March 8, 2017. http://www.ey.com
   Google Scholar
• Evald, M. R., H. A. Nissen, A. H. Clarke, and K. B. Munksgaard. 2014. “Reviewing Cross-Field Public Private Innovation Literature: Current Research Themes and Future Research Themes yet to Be Explored.” International Public Management Review 15 (2): 32–57.
   Google Scholar
• Evans, A. G., and N. P. Varaiya. 2003. “Anne Evans: Assessment of a Biotechnology Market Opportunity.” Entrepreneurship Theory and Practice 28 (1): 87–105. doi:10.1111/1540-8520.00033.
   Web of Science ®Google Scholar
• Ferlie, E., L. Fitzgerald, G. McGivern, S. Dopson, and C. Bennet. 2011. “Public Policy Networks and ‘Wicked Problems’: A Nascent Solution?” Public Administration 89 (2): 307–324. doi:10.1111/j.1467-9299.2010.01896.x.
   Web of Science ®Google Scholar
• Frost & Sullivan. 2009. Emerging Therapeutic Segments in the European Biopharmaceuticals Market. Accessed March 8, 2017. https://ww2.frost.com/
   Google Scholar
• Gans, J. S., and S. Stern. 2003. “The Product Market and the Market for “Ideas”: Commercialization Strategies for Technology Entrepreneurs.” Research Policy 32 (2): 333–350. doi:10.1016/S0048-7333(02)00103-8.
   Web of Science ®Google Scholar
• Grant, R. M., and B.-F. Charles. 2004. “A Knowledge Accessing Theory of Strategic Alliances.” Journal of Management Studies 41 (1): 61–84. doi:10.1111/j.1467-6486.2004.00421.x.
   Web of Science ®Google Scholar
• Gray, B. 1985. “Conditions Facilitating Interorganizational Collaboration.” Human Relations 38 (10): 911–936. doi:10.1177/001872678503801001.
   Web of Science ®Google Scholar
• Gulbrandsen, M., T. Thune, S. B. Borlaug, and J. Hanson. 2015. “Emerging Hybrid Practices in Public–Private Research Centres.” Public Administration 93 (2): 363–379. doi:10.1111/padm.12140.
   Web of Science ®Google Scholar
• Hefetz, A., and M. E. Warner. 2012. “Contracting or Public Delivery? the Importance of Service, Market, and Management Characteristics.” Journal of Public Administration and Research Theory 22: 289–317. doi:10.1093/jopart/mur006.
   Web of Science ®Google Scholar
• Henderson, R., and I. Cockburn. 1994. “Measuring Competence? Exploring Firm Effects in Pharmaceutical Research.” Strategic Management Journal 15 (S1): 63–84. doi:10.1002/smj.4250150906.
   Web of Science ®Google Scholar
• Higgins, C. D., and A. S. Huque. 2015. “Public Money and Mickey Mouse: Evaluating Performance and Accountability in the Hong Kong Disneyland Joint Venture Public–Private Partnership.” Public Management Review 17 (8): 1103–1123. doi:10.1080/14719037.2014.881533.
   Web of Science ®Google Scholar
• Hodge, G. A., and C. Greve. 2009. “Ppps: The Passage of Time Permits a Sober Reflection.” Economic Affairs 29 (1): 33–39. doi:10.1111/j.1468-0270.2009.01864.x.
   Google Scholar
• Kogut, B., and U. Zander. 1992. “”Knowledge of the Firm, Combinative Capabilities, and the Replication of Technology.”.” Organization Science 3 (3): 383–397. doi:10.1287/orsc.3.3.383.
   Web of Science ®Google Scholar
• Kola, I., and J. Landis. 2004. “Can the Pharmaceutical Industry Reduce Attrition Rates?” Nature Reviews Drug Discovery 3 (8): 711–715. doi:10.1038/nrd1470.
   PubMed Web of Science ®Google Scholar
• Lawrence, S. 2007. “Drug Output Slows in 2006.” Nature Biotechnology 25 (10): 1073–1073. doi:10.1038/nbt1007-1073.
   Google Scholar
• Lazarou, J., B. H. Pomeranz, and P. N. Corey. 1998. “Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-Analysis of Prospective Studies.” Journal of the American Medical Association 279 (15): 1200–1205. doi:10.1001/jama.279.15.1200.
   PubMed Web of Science ®Google Scholar
• Lichtenberg, F. R. 2005. “The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001.” International Journal of Health Care Finance and Economics 5 (1): 47–73. doi:10.1007/s10754-005-6601-7.
   PubMedGoogle Scholar
• Linden, R. M. 2003. Working across Boundaries: Making Collaboration Work in Government and Nonprofit Organizations. San Fransisco, CA: John Wiley & Sons.
   Google Scholar
• McCutchen, W. W., and P. M. Swamidass. 2004. “Motivation for Strategic Alliances in the Pharmaceutical/Biotech Industry: Some New Findings.” Journal of High Technology Management Research 15 (2): 197–214. doi:10.1016/j.hitech.2004.03.003.
   Google Scholar
• Meek, J. W., and W. H. Newell. 2005. “Complexity, Interdisciplinarity and Public Administration: Implications for Integrating Communities.” Public Administration Quarterly 29 (3/4): 321–349.
   Google Scholar
• Montaner, J. S. G., M. V. O’Shaughnessy, and M. T. Schechter. 2001. “Industry-Sponsored Research: A Double-Edged Sword.” The Lancet 358 (9296): 1893–1895. doi:10.1016/S0140-6736(01)06891-X.
   PubMed Web of Science ®Google Scholar
• Moore, M. H. 1995. Creating Public Value: Strategic Management in Government. Cambridge, MA: Harvard University Press.
   Google Scholar
• Nightingale, P., and P. Martin. 2004. “The Myth of the Biotech Revolution.” TRENDS in Biotechnology 22 (11): 564–569. doi:10.1016/j.tibtech.2004.09.010.
   PubMed Web of Science ®Google Scholar
• Owen-Smith, J., and W. W. Powell. 2003. “The Expanding Role of University Patenting in the Life Sciences: Assessing the Importance of Experience and Connectivity.” Research Policy 32 (9): 1695–1711. doi:10.1016/S0048-7333(03)00045-3.
   Web of Science ®Google Scholar
• Page, S. B., M. M. Stone, J. M. Bryson, and B. C. Crosby. 2015. “Public Value Creation By Cross‐Sector Collaborations: A Framework And Challenges Of Assessment.” Public Administration 93 (3): 715–732. doi:10.1111/padm.12161.
   Web of Science ®Google Scholar
• Pammolli, F., L. Magazzini, and M. Riccaboni. 2011. “The Productivity Crisis in Pharmaceutical R&D.” Nature Reviews Drug Discovery 10 (6): 428–438. doi:10.1038/nrd3405.
   PubMed Web of Science ®Google Scholar
• Paul, S. M., D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, and A. L. Schacht. 2010. “How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge.” Nature Reviews Drug Discovery 9: 203–214.
   PubMed Web of Science ®Google Scholar
• Pavlou, A. K., and M. J. Belsey. 2005. “The Therapeutic Antibodies Market to 2008.” European Journal of Pharmaceutics and Biopharmaceutics 59 (3): 389–396. doi:10.1016/j.ejpb.2004.11.007.
   PubMed Web of Science ®Google Scholar
• Pisano, G. P. 1997. “R&D Performance, Collaborative Arrangements and the Market for Know-How: A Test of the “Lemons” Hypothesis in Biotechnology”. SSRN Working Papers, Harvard Business School, Boston, MA.
   Google Scholar
• Powell, W. W., K. W. Koput, and S.-D. Laurel. 1996. “Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology.” Administrative Science Quarterly 41: 116–145. doi:10.2307/2393988.
   Web of Science ®Google Scholar
• Rasbash, J. C., W. J. Charlton, B. M. Healy, and B. Cameron. 2005. Mlwin Version 2.02. Bristol: Centre for Multilevel Modelling, University of Bristol.
   Google Scholar
• Reichert, J. M., and C. Paquette. 2003. “Clinical Development of Therapeutic Recombinant Proteins.” BioTechniques 35 (1): 176–185.
   PubMed Web of Science ®Google Scholar
• Reichert, J. M., C. J. Rosensweig, L. B. Faden, and M. C. Dewitz. 2005. “Monoclonal Antibody Successes in the Clinic.” Nature Biotechnology 23 (9): 1073–1078. doi:10.1038/nbt0905-1073.
   PubMed Web of Science ®Google Scholar
• Riccio, L. J. 2014. “Commentary: Public–Private Partnerships: Pitfalls and Possibilities.” Public Administration Review 74 (1): 50–51. doi:10.1111/puar.12169.
   Web of Science ®Google Scholar
• Rosenau, P. V. 2000. “The Strengths and Weaknesses of Public-Private Policy Partnerships.” In Public-Private Policy Partnerships, 217–242. Cambridge, MA: The MIT Press.
   Google Scholar
• Sampson, R. C. 2004. “Organizational Choice in R&D Alliances: Knowledge-Based and Transaction Cost Perspectives.” Managerial and Decision Economics 25 (6–7): 421–436. doi:10.1002/mde.1199.
   Google Scholar
• Saz-Carranza, A., and F. Longo. 2012. “Managing Competing Institutional Logics in Public–Private Joint Ventures.” Public Management Review 14 (3): 331–357. doi:10.1080/14719037.2011.637407.
   Web of Science ®Google Scholar
• Schaeffer, P. V., and S. Loveridge. 2002. “Toward an Understanding of Types of Public-Private Cooperation.” Public Performance & Management Review 26 (2): 169–189. doi:10.1177/1530957602238261.
   Google Scholar
• Shi, S.-J. 2016. “The Bounded Welfare Pluralism: Public–Private Partnerships under Social Management in China.” Public Management Review 1–16. doi:10.1080/14719037.2016.1183700.
   Web of Science ®Google Scholar
• Spear, B. B., M. Heath-Chiozzi, and J. Huff. 2001. “Clinical Application of Pharmacogenetics.” TRENDS in Molecular Medicine 7 (5): 201–204. doi:10.1016/S1471-4914(01)01986-4.
   PubMed Web of Science ®Google Scholar
• Teece, D. J. 1986. “Profiting from Technological Innovation: Implications for Integration, Collaboration, Licensing and Public Policy.” Research Policy 15 (6): 285–305. doi:10.1016/0048-7333(86)90027-2.
   Web of Science ®Google Scholar
• Torchia, M., A. Calabrò, and M. Mornera. 2015. “Public–Private Partnerships in the Health Care Sector: A Systematic Review of the Literature.” Public Management Review 17 (2): 236–261. doi:10.1080/14719037.2013.792380.
   Web of Science ®Google Scholar
• Van Noorden, R. 2015. “Interdisciplinary Research by the Numbers.” Nature 525 (7569): 306–307. doi:10.1038/525306a.
   PubMed Web of Science ®Google Scholar
• Vangen, S., J. P. Hayes, and C. Cornforth. 2015. “Governing Cross-Sector, Inter-Organizational Collaborations.” Public Management Review 17 (9): 1237–1260. doi:10.1080/14719037.2014.903658.
   Web of Science ®Google Scholar
• Warner, M. E., and G. Bel. 2008. “Competition or Monopoly? Comparing Privatization of Local Public Services in the US and Spain.” Public Administration 86 (3): 723–735. doi:10.1111/j.1467-9299.2008.00700.x.
   Web of Science ®Google Scholar
• Whittington, K. B., J. Owen-Smith, and W. W. Powell. 2009. “Networks, Propinquity, and Innovation in Knowledge-Intensive Industries.” Administrative Science Quarterly 54 (1): 90–122. doi:10.2189/asqu.2009.54.1.90.
   Web of Science ®Google Scholar
• Willems, J. 2016. “Debate: Should Public Management Research Be More Interdisciplinary?” Public Money & Management 36 (2): 76–78. doi:10.1080/09540962.2016.1118924.
   Web of Science ®Google Scholar
• Willmann, J. K., N. Van Bruggen, L. M. Dinkelborg, and S. S. Gambhir. 2008. “Molecular Imaging in Drug Development.” Nature Reviews Drug Discovery 7 (7): 591–607. doi:10.1038/nrd2290.
   PubMed Web of Science ®Google Scholar
• Woodcock, J., and R. Woosley. 2008. “The FDA Critical Path Initiative and Its Influence on New Drug Development.” Annual Review of Medicine 59: 1–12. doi:10.1146/annurev.med.59.090506.155819.
   PubMed Web of Science ®Google Scholar
• Woolf, S. H. 2008. “The Meaning of Translational Research and Why It Matters.” Journal of the American Medical Association 299 (2): 211–213.
   PubMed Web of Science ®Google Scholar
• Zhang, J., C. Baden-Fuller, and V. Mangematin. 2007. “Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry.” Research Policy 36 (4): 515–528. doi:10.1016/j.respol.2007.02.015.
   Web of Science ®Google Scholar